Pfizer COVID-19 vaccine only partially protects against Omicron - study

According to the manuscript, they observed a 41-fold decline in levels of neutralizing antibodies against the Omicron variant.

The Pfizer vaccine for children aged 5-11 (photo credit: AVSHALOM SASSONI/MAARIV)
The Pfizer vaccine for children aged 5-11
(photo credit: AVSHALOM SASSONI/MAARIV)

The Omicron variant of the coronavirus can partially evade the protection from Pfizer Inc and partner BioNTech's COVID-19 vaccine, the research head of a laboratory at Africa Health Research Institute in South Africa said on Tuesday.

Alex Sigal, a professor at the Africa Health Research Institute, said on Twitter there was "a very large drop" in the neutralization of the Omicron variant relative to an earlier strain of COVID. The lab tested blood from 12 people who had been vaccinated with the Pfizer/BioNTech vaccine, according to a manuscript posted on the website for his lab. The preliminary data in the manuscript has not yet been peer-reviewed.

Blood from five out of six people who had been vaccinated as well as previously infected with COVID-19 still neutralized the Omicron variant, the manuscript said.

According to the manuscript, they observed a 41-fold decline in levels of neutralizing antibodies against the Omicron variant.

Sigal said on Twitter that figure is likely to be adjusted after his lab does more experiments.

Syringes with needles are seen in front of a displayed stock graph and words ''Omicron SARS-CoV-2'' in this illustration taken, November 27, 2021. (credit: REUTERS/DADO RUVIC/ILLUSTRATION/FILE PHOTO)Syringes with needles are seen in front of a displayed stock graph and words ''Omicron SARS-CoV-2'' in this illustration taken, November 27, 2021. (credit: REUTERS/DADO RUVIC/ILLUSTRATION/FILE PHOTO)

The Omicron variant, first detected in southern Africa last month, has triggered alarms globally of another surge in infections, with more than two dozen countries from Japan to the United States reporting cases.

The World Health Organization on November 26 classified it as a "variant of concern" but said there was no evidence to support the need for new vaccines specifically designed to tackle the Omicron variant with its many mutations.

Sigal did not immediately respond to a Reuters request for comment.